Therapeutic compositions for intranasal administration of ketorolac

A composition, a nasal technique, applied in the field of pain treatment, can solve the problems such as the time of the maximum concentration of 5HT1D that no one has mentioned

Inactive Publication Date: 2007-12-05
ROXRO PHARMA INC
View PDF4 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

No data were provided to support this hypothesis, and no one mentioned the time to reach the maximum concentration of 5HT1D

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic compositions for intranasal administration of ketorolac
  • Therapeutic compositions for intranasal administration of ketorolac
  • Therapeutic compositions for intranasal administration of ketorolac

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0089] This example describes the preparation of compositions of the invention for nasal administration. Prepare solutions according to the proportions shown in Table 1. Lidocaine hydrochloride was added to the solution to obtain the compositions of the present invention shown in Table 2.

[0090] Table 1

[0091] Ketorolac Tromethamine, USP 15%

[0092] Sodium EDTA, NF 0.02%

[0093] Potassium Phosphate, NF (qs up to pH 7.2)

[0094] Water for Injection USP (appropriate amount) 100g

[0095] Table 2

[0096] Component I II III

[0097] Ketorolac Tromethamine, USP 15% 15% 15%

[0098] Sodium EDTA, NF 0.02% 0.02% 0.02%

[0099] Potassium phosphate, NF (as appropriate until pH 7.2)

[0100] Lidocaine hydrochloride 4% 5% 6%

[0101] Water for injection USP (appropriate amount) 100g 100g 100g

example 2

[0103] This example describes a phase I clinical study conducted to determine intrinsic activity (i.a.) when the presence of lidocaine hydrochloride in nasally administered ketorolac formulations had a negative impact on the PK profile of ketorolac (dual Blind, randomized 4-way crossover study). The results show that the PK profile is enhanced by the presence of the anesthetic lidocaine hydrochloride (5-6% w / v) in the preferred formulation and otherwise not negatively affected. In addition, the safety and tolerability data of the formulations were also evaluated.

[0104] The clinical study included 16 healthy volunteers recruited for the study, each volunteer receiving 4 nasal spray formulations, 3 of which were compositions representing aspects of the present invention. There is a rest period of 3-7 days between each administration. The 4 aqueous spray compositions were prepared as follows:

[0105] KT(1) L(2) NaEDTA(3) K 3 PO 4 (4) water (5)

[0106] A: 15% 0 0...

example 3

[0120] This example describes a study in postoperative patients to compare the safety, tolerability and pharmacokinetics (PK) of 3 intranasal (IN) ketorolac tromethamine formulations.

[0121] The study was a double-blind, parallel study in postoperative patients. Individuals received 1 of 3 IN ketorolac tromethamine formulations (30 mg) or placebo. Two of these formulations are preferred formulations of the invention. A total of 60 individuals were included in the study, with 15 individuals enrolled in each group. Each formulation was administered IN to each subject (one spray into each nostril).

[0122] Eligible postoperative patients for this study included those aged 18 to 60 years who were within 20% of ideal body weight (MetLife Male and Female Height and Weight Table (1999 edition)).

[0123] Each individual is randomly assigned to receive one of the following treatments:

[0124] □ Treatment A (composition known in the art) - single IN dose of 30 mg ketorolac trom...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Therapeutic compositions, particularly sprayable aqueous compositions, comprise ketorolac or a pharmaceutically acceptable salt, in combination with a local anesthetic, such as lidocaine hydrochloride. The compositions are nasally administered to a subject in need thereof to treat pain or inflammation and have the benefit of reduced stinging and improved efficacy, compared to known nasally administered compositions.

Description

technical field [0001] The present invention relates to a therapeutic composition having anesthetic and anti-inflammatory activity and suitable for intranasal administration comprising as active ingredients ketorolac or a pharmaceutically acceptable salt thereof and a local anesthetic to reduce stinging sensation and enhance efficacy. The present invention also relates to providing a medical method for nasally administering the composition to a subject for the treatment of pain, wherein the subject has reduced stinging sensation and improved efficacy compared to known compositions. Background technique [0002] Ketorolac or 5-benzoyl-2,3-dihydro-1H-pyrrolazine-1-carboxylic acid having the following formula (I): [0003] [0004] It has been known for many years (US Patent No. 4,089,969) and is used in human therapy as a tromethamine salt with analgesic and anti-inflammatory effects. US Patent No. 4,089,969 is incorporated herein by reference. [0005] The racemic form a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/407A61P25/06A61K31/167A61P29/00A61K9/08
CPCA61K9/0043A61K31/167A61K31/407A61P25/00A61P25/04A61P25/06A61P29/00A61K2300/00
Inventor 罗杰·怀廷拉马钱德兰·提鲁科特
Owner ROXRO PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap